GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » Profitability Rank

Mural Oncology (Mural Oncology) Profitability Rank : 1 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology Profitability Rank?

Mural Oncology has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Mural Oncology's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Mural Oncology's Piotroski F-Score is 9999.


Competitive Comparison of Mural Oncology's Profitability Rank

For the Biotechnology subindustry, Mural Oncology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mural Oncology's Profitability Rank Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mural Oncology's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Mural Oncology's Profitability Rank falls into.



Mural Oncology Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Mural Oncology has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Mural Oncology's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-34.033 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Mural Oncology has an F-score of 9999. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Mural Oncology Profitability Rank Related Terms

Thank you for viewing the detailed overview of Mural Oncology's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Mural Oncology (Mural Oncology) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10 Earlsfort Terrace, Dublin, IRL, D02 T380
Website
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging their core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. The Company operates as one business segment, which is the business of developing medicines designed to address unmet medical needs of patients in the area of oncology.

Mural Oncology (Mural Oncology) Headlines